We would love to hear your thoughts about our site and services, please take our survey here.
Well the sooner 1801 progresses the better
https://www.msn.com/en-gb/health/medical/gamma-variant-could-have-high-attack-rate-even-in-fully-vaccinated-people-new-study/ar-AAMvrcl?ocid=entnewsntp
https://www.privateislandsonline.com/search?view%5Bmap%5D=0&availability=sale®ion=&q=&price_range=0%3A50000000&size_range=0%3A1000
To go with the yachts ;)
ummm...;)
https://www.privateislandsonline.com/asia/maldives/amillarah-private-islands
https://optionscalltoday.com/2021/06/21/uk-investors-are-buying-sareum-holdings-should-i/
Sareum has already said that the completion of preclinical research is “topic to profitable progress”.
Written by someone who needs to stick with FT100..
more positive than negative, but good to see were getting noticed ;)
Sierra silence could be just as golden for SRA737
https://www.businesswire.com/news/home/20210722005267/en/
Again not a sniff of 737 in their pipeline, why not brag about it??
Sitting on a golden eggs comes to mind, about to hatch though ;)
On licencing deal nearly Won't be long for the 737 news
What's worth more, 1801 or 737? ;)
I wouldn't want to bet on which news drops 1st for Sareum, their all in pole position ;)
https://www.msn.com/en-gb/news/world/world-faces-going-back-to-square-one-as-more-covid-variants-emerge-who-warns/ar-AAMr8Jc?ocid=entnewsntp
£2 a pill please ;)
We're all mere Immortals, news can drop any time.. lets do a rhyme
Covid came along and turns the world upside down,
With long covid, live or die
New mutations, some will survive
But a weak TYK2 immune could be fatal to you
WHO knows with the next combination will bring
Lets take a breath (if you can!!) Its about surviving..
Come on 1801, give us the life line,
From T2's Yacht's to brewery's we've read
No more needs to be said ;)
Big pharma's have dished out their rejects to try
Riddled with side effects, again live or die
Hoping they work and guess what, human life's!!
Herd immunity, we sacrifice our life's
Lets get back to normal haha with he governments lies...
Sareum 1801, well lets give it a try ;)
Wishing everyone single LTH the very best, health wealth and happiness for the future.
This is looking more and more likely end game is near ;)
The team highlighted one of these two loci in particular, near the FOXP4 gene, which is linked to lung cancer. The FOXP4 variant associated with severe Covid-19 increases the gene’s expression, suggesting that inhibiting the gene could be a potential therapeutic strategy. Other loci associated with severe Covid-19 included DPP9, a gene also involved in lung cancer and pulmonary fibrosis, and TYK2, which is implicated in some autoimmune diseases.
“We’d like to aim to get a good handful of very concrete therapeutic hypotheses in the next year,” Daly said. “Realistically, we will most likely be addressing Covid-19 as a serious health concern for a long time. Any therapeutic that emerges this year, for example from repurposing an existing drug based on clear genetic insights, would have a great impact.”
https://www.ddw-online.com/genomics-analysis-on-why-covid-19-affects-people-so-differently-12405-202107/
Any drug that emerges, how about SDC1801........would have a great impact
TYK2 Tock, were ready for a news drop ;)
Agile clinical trials, reminder...
Think our spot has been saved in Pole position ;)
https://clinicaltrials.gov/ct2/show/NCT04746183
Just need to cross the T's and dot the i's ;)
https://directorsblog.nih.gov/tag/tyk2/
More TYK2 validation
Brighty, thank you for sharing your well constructed thoughts. Really appreciated, easily see how easily Sareum could be joining a few that have just experienced a trip to space ;)
Q. If TO is in neg', how could this be valued per share with so much going on? More and more money keeps landing. Humongous delayed trades popping up, mind boggles. I'd prefer a complete TO, just to take away the stress on my ticker ;)
WIP, very true, he's out of his depth...
Covid Toes anyone. 1st I've heard of it!!
https://www.msn.com/en-gb/health/medical/teenager-is-barely-able-to-walk-because-of-covid-toes/ar-AAMjJf6?ocid=entnewsntp
I like this little chart and article
https://ukinvestormagazine.co.uk/investment-to-improve-drug-development-boosts-sareum-holdings-share-price/
or maybe just the editors surname lol ;)
Another great RNS today, reinforcing the rerate ;)
From todays RNS:
The net proceeds from the Subscription will be used to progress the Company's SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes as well as for working capital purposes. As noted in the Company's Trading Update of 25 May 2021, the Company is targeting the completion of preclinical studies for SDC-1801 in Q3 2021, subject to successful progress. Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised.
Covid play, no brainer Agile, everything else will just keep the multi bags flowing.
Great posts today guys, keep up the fantastic work
Laymans terms, read below, Candidate-Specific Trial 1 (CST-1): TBC:
AGILE is a multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II Bayesian randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19.
This study allows for the assessment of many candidates at different doses, with the ability to add candidates as they are identified or drop them as their evaluation is completed. Promising candidates will move to the an external trial for further evaluation in the phase II/III setting.
Each candidate will be evaluated in its own trial, randomising between candidate and control with 2:1 allocation in favour of the candidate. Each dose will be assessed for safety sequentially in cohorts of 6 patients. Once a phase II dose has been identified we will assess efficacy by seamlessly expanding into a larger cohort.
AGILE is completely flexible in that the core design in the master protocol (as has been explained above) can be adapted for each candidate based on prior knowledge of the candidate - i.e. population, primary endpoint and sample size can be amended. This will be detailed in each candidate-specific trial protocol of the master protocol.
Candidate-Specific Trial 1 (CST-1): TBC
Candidate-Specific Trial 2 (CST-2): Open-label 2:1 randomised controlled phase I of EIDD-2801 versus standard of care followed by a 1:1 blinded controlled parallel group Phase II trial of EIDD-2801 versus placebo. A phase I will be carried out to confirm the optimal dose in this group. Following a safety review, EIDD-2801 will be tested for efficacy in a blinded placebo controlled randomised phase II trial.
Candidate-Specific Trial 3 (CST-3A): Multicentre, Adaptive, Phase I trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19
Candidate-Specific Trial 3 (CST-3B): A Randomized, Multicentre, Seamless, Adaptive, Phase I/II trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19
Candidate-Specific Trial 5 (CST-5): Randomized, Multicentre, Seamless, Adaptive, Phase I/II Platform Study to Determine the Phase II dose of VIR-7832, and Evaluate the Safety and Efficacy of VIR-7831 and VIR-7832 for the Treatment of COVID-19
so these trails have already started, except for Candidate-Specific Trial 1 (CST-1): TBC?
I wonder why ;)
Candidate-Specific Trial 1 (CST-1): TBC
https://clinicaltrials.gov/ct2/show/NCT04746183
What I meant was CST Trial "1" is TBC... so its not confirmed but my thinking is its ready for 1801, but details are still to be confirmed, Preclinical was 75% paid for by UKRI, AGILE want to take it forward (why not it bloody works!!) but maybe Sareum are holding things up, that could be down to many reasons, but licencing deal is my thinking, and it could be still Agile but through a big pharma.
Good luck next week everyone, T2 hope you recover promptly.
Don't let the little ones get under your skin, just don't reply ;)
Candidate-Specific Trial 1 (CST-1): TBC
https://clinicaltrials.gov/ct2/show/NCT04746183
TBC
Could this be our 1801?